Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease

Blood

Volumn 98, Issue 7, 2001, Pages 2269-2271

  Seidel, Carina ^a,b,c,d,e   Hjertner, Oyvind ^a,b,c,d,e,f   Abildgaard, Niels ^a,b,c,d,e   Heickendorff, Lene ^a,b,c,d,e   Hjorth, Martin ^a,b,c,d,e   Westin, Jan ^a,b,c,d,e   Nielsen, Johan Lanng ^a,b,c,d,e   Hjorth Hansen, Henrik ^a,b,c,d,e   Waage, Anders ^a,b,c,d,e   Sundan, Anders ^a,b,c,d,e   Børset, Magne ^a,b,c,d,e  

^a Institute of Cancer Research and Molecular Biology   (Norway)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Lidkoping Hospital   (Sweden)

^d Department of Hematology ^*  (Norway)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROCOLLAGEN;

ADULT; AGED; ARTICLE; BONE ATROPHY; BONE REMODELING; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; SURVIVAL; WORLD HEALTH ORGANIZATION;

EID: 0035496947     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.7.2269     Document Type: Article

References (20)

1. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93:165-176.
2. Hofbauer LC, Khosla S, Dunstan CR, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res. 2000;15:2-12.
3. The Nordic Myeloma Study Group. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. Ann Intern Med. 1996;124:212-222.
4. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842-854.
5. Turesson I, Abildgaard N, Ahlgren T, et al. Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. Br J Haematol. 1999;106:1005-1012.
6. Seidel C, Sundan A, Hjorth M, et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood. 2000;95:388-392.
7. Abildgaard N, Bentzen SM, Nielsen JL, Heickendorff L. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal propeptide of type I collagen (ICTP). Br J Haematol. 1997;96:103-110.
8. Mundy GR, Ralsz LG, Cooper RA, et al. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med. 1974;291:1041-1046.
9. Hjertner O, Torgersen ML, Seidel C, et al. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. Blood. 1999;94:3883-3888.
10. Michigami T, Shimizu N, Williams PJ, et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood. 2000;96:1953-1960.
11. Bataille R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoctasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest. 1991;88:62-66.
12. Udagawa N, Takahashi N, Yasuda H, et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology. 2000;141:3478-3484.
13. Yano K, Tsuda E, Washida N, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res. 1999;14:518-527.
14. Borset M, Hjertner O, Yaccoby S, Epstein J, Sanderson RD. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood. 2000;96:2528-2536.
15. Fuki IV, Kuhn KM, Lomazov IR, et al. The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. J Clin Invest. 1997;100:1611-1622.
16. Fuki IV, Meyer ME, Williams KJ, Transmembrane and cytoplasmic domains of syndecan mediate a multi-step endocytic pathway involving detergentinsoluble membrane rafts. Biochem J. 2000;351: 607-612.
17. Bataille R, Chappard D, Marcelli C, et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol. 1989;7:1909-1914.
18. Risteli L, Risteli J. Biochemical markers of bone metabolism. Ann Med. 1993;25:385-393.
19. Abildgaard N, Glerup H, Rungby J, et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol. 2000;64:121-129.
20. Honore P, Luger NM, Sabino MA, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med. 2000;6:521-528.